文献速递神经免疫

Satralizumab单药治疗视神经脊髓炎谱系疾病的安全性与疗效:随机双盲多中心安慰剂对照3期试验

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
PubMed 文献 · Lancet Neurol · 2020-01-01

本3期双盲安慰剂对照试验纳入168例筛选患者中的95例成人视神经脊髓炎谱系疾病(NMOSD)患者,按2:1随机接受Satralizumab 120 mg皮下注射或安慰剂,禁止联用免疫抑制剂。

要点

  • Satralizumab组协议定义复发19例(30%),安慰剂组16例(50%)。
  • 两组严重不良事件及导致退出不良事件发生率相似,安全性特征良好。

核心结论

  • Satralizumab单药治疗在总体试验人群中较安慰剂降低NMOSD复发率,且安全性特征良好。
  • Satralizumab有潜力成为NMOSD患者有价值的治疗选择。

研究设计与样本

  • 3期双盲、安慰剂对照、平行组试验,在13个国家44个研究中心开展。
  • 纳入18-74岁水通道蛋白-4抗体阳性或阴性NMOSD成人,随机按2:1分配至Satralizumab 120 mg或安慰剂皮下注射。
  • 95例(占168例筛选者的57%)被随机分配:63例至Satralizumab组,32例至安慰剂组。

主要发现

  • 协议定义复发在Satralizumab组为19例(30%),安慰剂组为16例(50%)。

临床怎么用

  • 对于水通道蛋白-4抗体阳性或阴性的NMOSD成人患者,Satralizumab单药可考虑作为降低复发风险的治疗选择。
  • 治疗期间需关注不良事件,但严重不良事件及导致退出不良事件发生率与安慰剂相似。

局限性

  • 试验禁止联用免疫抑制剂,结果外推至联合治疗情境需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Satralizumab, a humanised monoclonal antibody targeting the interleukin-6 receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD) when added to immunosuppressant therapy. This study assessed the safety and efficacy of satralizumab monotherapy in patients with the disorder. METHODS: In this phase 3, double-blind, placebo-controlled, parallel-group trial, we enrolled adults aged 18-74 years with aquaporin-4 antibody seropositive or seronegative NMOSD at 44 investigational sites in 13 countries. Eligible participants had experienced at least one documented NMOSD attack or relapse in the past 12 months and had a score of 6·5 or less on the Expanded Disability Status Scale. Exclusion criteria included clinical relapse 30 days or fewer before baseline. Participants were randomly assigned (2:1) to receive satralizumab 120 mg or visually matched placebo subcutaneously at weeks 0, 2, 4, and every 4 weeks thereafter. Taking immunosuppressants concomitantly was prohibited. The primary endpoint was time to the first protocol-defined relapse, based on the intention-to-treat population and analysed with stratification for two randomisation factors (previous therapy for prevention of attacks and nature of the most recent attack). Safety was assessed in all participants who received at least one dose of satralizumab or placebo. The double-blind phase was due to last until 44 protocol-defined relapses occurred or 1·5 years after random assignment of the last patient enrolled, whichever occurred first; participants could enter an open-label phase after the occurrence of a protocol-defined relapse or at the end of the double-blind phase. The study is registered with ClinicalTrials.gov, NCT02073279. FINDINGS: 95 (57%) of 168 screened participants were randomly assigned to treatment (63 to satralizumab; 32 to placebo) between Aug 5, 2014, and April 2, 2017. Protocol-defined relapses occurred in 19 (30%) patients receiving satralizumab and 16 (50%) receiving placebo (hazard ratio 0·45, 95% CI 0·23-0·89; p=0·018). 473·9 adverse events per 100 patient-years occurred in the satralizumab group, as did 495·2 per 100 patient-years in the placebo group; the incidence of serious adverse events and adverse events leading to withdrawal was similar between groups. INTERPRETATION: Satralizumab monotherapy reduced the rate of NMOSD relapse compared with placebo in the overall trial population, with a favourable safety profile. The patient population included a ratio of aquaporin-4 antibody seropositive and seronegative patients that was reflective of clinical practice. Satralizumab has the potential to become a valuable treatment option for patients with NMOSD. FUNDING: Chugai Pharmaceutical (Roche).

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020. PMID: 32333898. doi:10.1016/S1474-4422(20)30078-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。